5 oct 2016 año - FDA convened a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management to discuss naloxone products intended for use in the community, specifically the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in all ages.
Añadido al timeline:
fecha:
5 oct 2016 año
Ahora mismo
~ 9 years ago